Gracell Biotechnologies Inc. (GRCL) News
Filter GRCL News Items
GRCL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GRCL News Highlights
- GRCL's 30 day story count now stands at 16.
- Over the past 16 days, the trend for GRCL's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- The most mentioned tickers in articles about GRCL are AZN, CVR and DEC.
Latest GRCL News From Around the Web
Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Gracell downgrade, Fusion upgrade: Wall Street's top analyst callsGracell downgrade, Fusion upgrade: Wall Street's top analyst calls |
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 BillionAstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion. |
These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and MoreRayzeBio surges after reaching an agreement to be acquired by Bristol Myers Squibb for $62.50 a share in cash, while Shanghai-based Gracell Biotechnologies is being bought by AstraZeneca in a deal valued at up to $1.2 billion. |
US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in viewU.S. stocks extended their rally on Tuesday, kicking off the final week of 2023 with expectations that the Federal Reserve will begin cutting interest rates as soon as March. All three major U.S. stock indexes rose in light trading a day after the Christmas holiday, with the S&P 500 touching its highest intraday level since January 2022. On Friday, the three indexes notched their eighth straight weekly gains - their longest weekly winning streaks in years - as economic data indicated inflation is easing down closer to the Fed's average annual 2% target. |
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy GoalsAstraZeneca announced Tuesday it would acquire Gracell Biotechnologies in a deal valued at up to $1.2 billion. Gracell is a Chinese biopharmaceutical company that focuses on cancer drug development. AstraZeneca said in a press release that it plans on buying the company to further its cell therapy ambitions. |
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell BiotechnologiesAstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio. The deal value is $2.00/share (equivalent to $10/ADS ADS of Gracell) plus a non-tradable contingent value right of $0.30/share (equivalent to $1.50/ADS of Gracell) in cash. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a clinical-stage FasTCAR-enabled BCMA, and CD19 dual-targeting autologou |
Can AstraZeneca's Deal to Buy Gracell Biotechnologies Perk Up Its Price?AstraZeneca has announced here on Tuesday that it is going to buy Gracell Biotechnologies for $1.2 billion. In this daily bar chart of AZN, below, I can see that prices have been in a downward path since April. The daily On-Balance-Volume (OBV) line shows us a choppy rise since July as buyers of AZN have been more aggressive than sellers. |
AstraZeneca set to make one of its first acquisitions in ChinaAstraZeneca is set to make one of its first acquisitions in China, announcing plans to acquire Gracell Biotechnologies for up to $1.2bn to increase its investment in cell therapies for treating cancer. The Anglo-Swedish drugmaker has been trying to use its status as one of the largest drugmakers in China by sales to hunt for potential deals. |
CORRECTED-UPDATE 1-AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln dealAstraZeneca said on Tuesday it will buy China-based Gracell Biotechnologies for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions. The cash deal aimed at bolstering AstraZeneca's portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met. "The proposed acquisition of Gracell will complement AstraZeneca's existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies in solid tumours", AstraZeneca's Oncology R&D Vice President Susan Galbraith said in a statement. |
AstraZeneca to Buy Gracell Biotechnologies for $1.2 BillionAstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business. |